Abstract
Mycobacterium tuberculosis (MTB), agent of tuberculosis (TB), is responsible for the death of around 2-3 million people annually and a global economic toll of ~$12 billion each year. For more than 50 years after the introduction of rifampicin (RMP) in 1960, no new drug had been developed against TB. All the need of a new molecule, led to quickly TMC-207 approval by the FDA (Food and Drug Administration), which was one of the compounds in clinical phase, becoming the first drug to be used only against multidrug resistant TB (MDR-TB), called "Sirturo". Our group through many collaborations has been seeking new bioactive molecules against TB, performing the screening of more than 3,000 different compounds in the last three years. Among our background study, as objective of this study, we selected three different classes of molecules unpublished addressing two major areas of Medicinal Chemistry (inorganic and organic synthetic) that were highly promising studies both in vitro and in vivo. The challenge will be to apply all existing methodologies within our pipeline and add new methodologies that constrain the activity of compounds in all physiological profiles of susceptible and resistant MTB active beyond the state latency, virulence mechanisms, such as efflux pump machinery, metabolism and pharmacokinetic profile as well as the incorporation of compounds in microemulsions. Achieving these aims we hope indicate a new candidate(s) for anti-TB drug. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |